Pharmaceutical

Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio

The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.

Jun 22, 2024 - 04:00
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.
Read the original article

Tags:

Previous Article

Sarepta’s Elevidys secures US label expansion for DMD

Next Article

WHO warns of “harmful” fake Ozempic in circulation in Americas and Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In early glimpse at data, Akili’s video game shows positive results with adults with ADHD

STAT+: In early glimpse at data, Akili’s video game sho...

May 3, 2023

Critics and defenders weigh in on Stanford president’s resignation after research investigation

Critics and defenders weigh in on Stanford president’s ...

Jul 20, 2023

NSCF embarks on fifth flight to investigate neurodegenerative disorders in space

NSCF embarks on fifth flight to investigate neurodegene...

Jan 19, 2024